Evaluation of a comprehensive information and assistance program for patients with schizophrenia treated with long-acting injectable antipsychotics

References

• National Alliance on Mental Illness. Mental Illness Facts and Numbers. 2013. Available at: http://www2.nami.org/factsheets/mentalillness_factsheet.pdf. 2013 [Last accessed 14 April 2015]
   Google Scholar
• National Institute of Mental Health. What is Schizophrenia? 2015. Available at: http://www.nimh.nih.gov/health/topics/schizophrenia/index.shtml [Last accessed 14 April 2015]
   Google Scholar
• Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004;161:692-9
   PubMed Web of Science ®Google Scholar
• Csernansky JG, Schuchart EK. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs 2002;16:473-84
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Zhu B, Faries DE, et al. Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia. BMC Res Notes 2009;2:6
   PubMedGoogle Scholar
• Kazadi NJB, Moosa MYH, Jeenah FY. Factors associated with relapse in schizophrenia. S Afr J Psychiatry 2008;14:52-62
   Web of Science ®Google Scholar
• Lafeuille MH, Laliberte-Auger F, Lefebvre P, et al. Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis. BMC Psychiatry 2013;13:221
   PubMed Web of Science ®Google Scholar
• Botha UA, Koen L, Joska JA, et al. The revolving door phenomenon in psychiatry: comparing low-frequency and high-frequency users of psychiatric inpatient services in a developing country. Soc Psychiatry Psychiatr Epidemiol 2010;45:461-8
   PubMed Web of Science ®Google Scholar
• Higashi K, Medic G, Littlewood KJ, et al. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol 2013;3:200-18
   PubMedGoogle Scholar
• Velligan DI, Mueller J, Wang M. Use of environmental supports among patients with schizophrenia. Psychiatr Serv 2006;57:219-24
   PubMed Web of Science ®Google Scholar
• Velligan DI, Weiden PJ, Sajatovic M, et al. Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines. J Psychiatr Prac 2010;16:306-24
   PubMed Web of Science ®Google Scholar
• Prikryl R, Prikrylova KH, Vrzalova M, Ceskova E. Role of long-acting injectable second-generation antipsychotics in the treatment of first-episode schizophrenia: a clinical perspective. Schizophr Res Treat 2012;2012:764769
   PubMedGoogle Scholar
• Llorca PM, Abbar M, Courtet P, et al. Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry 2013;13:340
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Nitta M, Borenstein M, et al. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry 2013;74:957-65
   PubMed Web of Science ®Google Scholar
• Taylor M, Ng KY. Should long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review. Aust NZ J Psychiatry 2013;47:624-30
   PubMed Web of Science ®Google Scholar
• Velligan DI, Medellin E, Draper M, et al. Barriers to, and strategies for, starting a long acting injection clinic in a community mental health center. Community Ment Health J 2011;47:654-9
   PubMed Web of Science ®Google Scholar
• Getzen H, Beasley M, D'Mello DA. Barriers to utilizing long-acting injectable antipsychotic medications. Ann Clin Psychiatry 2013;25:E1-6
   PubMedGoogle Scholar
• Shuler KM. Approaches to improve adherence to pharmacotherapy in patients with schizophrenia. Patient Prefer Adher 2014;8:701-14
   PubMed Web of Science ®Google Scholar
• Goldman DP, Dirani R, Fastenau J, Conrad RM. Do strict formularies replicate failure for patients with schizophrenia? Am J Manag Care 2014;20:219-28
   PubMed Web of Science ®Google Scholar
• Haddad PM, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas 2014;5:43-62
   PubMedGoogle Scholar
• National Alliance on Mental Illness. Prescription drug assistance. 2015. Available at: http://www2.nami.org/Template.cfm?section=about_medications&Template=/ContentManagement/contentDisplay.cfm&ContentID=19169 [Last accessed 14 April 2015]
   Google Scholar
• Valenstein M, Kavanagh J, Lee T, et al. Using a pharmacy-based intervention to improve antipsychotic adherence among patients with serious mental illness. Schizophr Bull 2011;37:727-36
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services Centers for Disease Control and Prevention. Office of the Director, Office of Strategy and Innovation. Introduction to program evaluation for public health programs: a self-study guide. Atlanta, GA: Centers for Disease Control and Prevention, 2011
   Google Scholar
• Janssen Pharmaceuticals Inc. Invega Sustenna (paliperidone palmitate) extended-release injectable suspension, for intramuscular use [package insert]. Titusville, NJ: Janssen Pharmaceuticals Inc., 2014
   Google Scholar
• Janssen Pharmaceuticals Inc. Risperdal Consta (risperidone) long-acting injection [package insert].Titusville, NJ: Janssen Pharmaceuticals Inc., 2012
   Google Scholar
• Fenton WS. Evolving perspectives on individual psychotherapy for schizophrenia. Schizophr Bull 2000;26:47-72
   PubMed Web of Science ®Google Scholar
• Frank AF, Gunderson JG. The role of the therapeutic alliance in the treatment of schizophrenia. Relationship to course and outcome. Arch Gen Psychiatry 1990;47:228-36
   PubMed Web of Science ®Google Scholar
• Fenton WS, McGlashan TH, Victor BJ, Blyler CR. Symptoms, subtype, and suicidality in patients with schizophrenia spectrum disorders. Am J Psychiatry 1997;154:199-204
   PubMed Web of Science ®Google Scholar
• Petersen AM, Nau DP, Cramer JA. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10:3-12
   PubMed Web of Science ®Google Scholar
• Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006;40:1280-8
   PubMed Web of Science ®Google Scholar
• Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44-7
   PubMed Web of Science ®Google Scholar
• NCQA. Adherence to Antipsychotic Medications for People with Schizophrenia 2013. Available at: http://www.ncqa.org/ReportCards/HealthPlans/StateofHealthCareQuality/2014TableofContents/AntipsychoticMedications.aspx [Last accessed 10 April 2015]
   Google Scholar
• Andersen R, Newman JF. Societal and individual determinant of medical care utilization in the United States. Milbank Quarterly 2005;83:1-28
   Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
   PubMed Web of Science ®Google Scholar
• Kaplan G, Casoy J, Zummo J. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adher 2013;7:1171-80
   PubMed Web of Science ®Google Scholar
• Polinski JM, Wang PS, Fischer MA. Medicaid's prior authorization program and access to atypical antipsychotic medications. Health Aff (Millwood) 2007;26:750-60
   PubMed Web of Science ®Google Scholar
• Huskamp HA, Stevenson DG, Donohue JM, et al. Coverage and prior authorization of psychotropic drugs under Medicare Part D. Psychiatr Serv 2007;58:308-10
   PubMed Web of Science ®Google Scholar
• The Patient Protection and Affordable Care Act. 2015:11-66
   Google Scholar
• American Pharmacists Association. National Community of Pharmacists Association. Media Kit. 2015. Available at: http://www.americaspharmacist.net/ncpa_media_kit.pdf [Last accessed 14 April 2015]
   Google Scholar
• Kaiser Family Foundation. Mental Health Care Health Professional Shortage Areas. 2014. Available at: http://kff.org/other/state-indicator/mental-health-care-health-professional-shortage-areas-hpsas [Last accessed 14 April 2015]
   Google Scholar
• Poirier S, Buffington DE, Memoli GA. Billing third party payers for pharmaceutical care services. J Am Pharm Assoc (Wash) 1999;39:50-64
   PubMedGoogle Scholar
• Markowitz M, Karve S, Panish J, et al. Antipsychotic adherence patterns and health care utilization and costs among patients discharged after a schizophrenia-related hospitalization. BMC Psychiatry 2013;13:246
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Zhu B, Faries DE, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry 2010;10:2
   PubMed Web of Science ®Google Scholar